GW&K Investment Management LLC Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

GW&K Investment Management LLC lowered its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 14.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,080,538 shares of the specialty pharmaceutical company’s stock after selling 184,268 shares during the quarter. GW&K Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $51,639,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SUPN. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after purchasing an additional 277 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Supernus Pharmaceuticals by 2.0% during the third quarter. Amalgamated Bank now owns 16,030 shares of the specialty pharmaceutical company’s stock valued at $766,000 after purchasing an additional 313 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Supernus Pharmaceuticals by 4.9% during the second quarter. Bank of Montreal Can now owns 10,144 shares of the specialty pharmaceutical company’s stock valued at $320,000 after buying an additional 475 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $55.58 on Thursday. The company has a market capitalization of $3.19 billion, a PE ratio of -81.73, a price-to-earnings-growth ratio of 1.70 and a beta of 0.70. The business’s fifty day moving average is $50.89 and its 200 day moving average is $48.62. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68.

Analysts Set New Price Targets

A number of brokerages have weighed in on SUPN. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus boosted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,185 shares of company stock valued at $1,268,022 over the last quarter. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.